HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CVS Augments Anti-Aging Skin Care Lineup With Skin Effects Launch

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

CVS is launching its premier private label skin care collection, skin effects by Dr. Jeffrey Dover, touted as the first dermatologist brand available at mass, the retailer said during a June 29 press event in New York City

You may also be interested in...



Skin Effects Summer Launches Include Products To Target Redness

Skin effects by Dr. Jeffrey Dover will add anti-aging formulas targeting redness to its line of mass market skin care products next month

Skin Effects Summer Launches Include Products To Target Redness

Skin effects by Dr. Jeffrey Dover will add anti-aging formulas targeting redness to its line of mass market skin care products next month

Patricia Wexler Skin Care Treats Inflammation With MMP Inhibitors

Patricia Wexler M.D. Dermatology skin care is formulated with proprietary MMPi technology to inhibit matrix metalloproteinases, reducing inflammation and rejuvenating skin at the structural level, according to Bath & Body Works

Table

View full table

Tags:
Latest Headlines

Cosmetic And Personal Care Trademark Review: 16 April

Health And Wellness Weekly Trademarks Review: 16 April

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Prestige Expands UK Eye Care Range In Response To Consumer Demand

See All
UsernamePublicRestriction

Register

RS013168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By